---
title: "Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286560395.md"
description: "Alumis (ALMS) reported a Q1 net loss of $93.1 million, an improvement from a $99 million loss a year prior. Revenue fell to $1.7 million from $17.4 million, below the expected $2.1 million. The company holds $569.5 million in cash and expects to fund operations through Q4 2027. Shares dropped 2% in premarket trading."
datetime: "2026-05-15T11:44:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286560395.md)
  - [en](https://longbridge.com/en/news/286560395.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286560395.md)
---

# Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell

07:44 AM EDT, 05/15/2026 (MT Newswires) -- Alumis ( ALMS ) reported a Q1 net loss late Thursday of $93.1 million, narrowing from a loss of $99 million a year earlier.

Analysts polled by FactSet expected a loss of $93.6 million.

Revenue for the quarter ended March 31 was $1.7 million, down from $17.4 million a year earlier.

Analysts surveyed by FactSet expected $2.1 million.

The company had cash, cash equivalents and marketable securities of $569.5 million as of March 31.

Alumis ( ALMS ) continues to expect its existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditure requirements into Q4 2027, it said.

The company's shares were down 2% in premarket activity Friday.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)